FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number: 3235-0							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Strem Brian M. (Last) (First) (Middle) C/O KIORA PHARMACEUTICALS, INC						Issuer Name and Ticker or Trading Symbol KIORA PHARMACEUTICALS INC [KPRX] Jane of Earliest Transaction (Month/Day/Year) 10/21/2022									all applicab Director Officer (g below)	ive title	10% Owner Other (specify below)		
1371 E. 2100 SOUTH, SUITE 200 (Street) SALT LAKE CITY (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indiv	dual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date					Fransaction te onth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)				ities Acquired (A) or d Of (D) (Instr. 3, 4 and 5) (A) or (D) Price		4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)				7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock 10/2					/21/2022				Α		12,50	0(1)	A	\$ <mark>0</mark>	13,183			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)			3A. Deemed Execution Dat if any (Month/Day/Ye	Co	ransaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)		•	Securities Underly Derivative Securit 3 and 4)		erlying	ying Derivative Security (Instr. 5)		er of e s allly g i ion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	de	v	(A)	(D)	Date Exercisal		Expiration Date	Title		or Number of Shares					
Stock Option (right to buy)	\$6.78	10/21/2022			A		18,750		(2)		0/21/2032		mmon tock	18,750	\$0	18,75	0	D	

Explanation of Responses:

- 1. Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of October 21, 2023, October 21, 2024 and October 21, 2024
- 21, 2025, subject to the reporting person's continuous service through each such vesting date.
- 2. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on October 21, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.

/s/ Melissa Tosca, Attorney-in-Fact
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.